Sock Chua - Koninklijke Philips Independent Member of the Supervisory Board
| PHG Stock | USD 26.38 0.07 0.27% |
Insider
Sock Chua is Independent Member of the Supervisory Board of Koninklijke Philips NV since 2021.
| Age | 63 |
| Tenure | 3 years |
| Address | Philips Center, Amsterdam, Netherlands, 1096 BC |
| Phone | 31 20 597 7777 |
| Web | https://www.philips.com |
Koninklijke Philips Management Efficiency
The company has Return on Asset of 0.0136 % which means that on every $100 spent on assets, it made $0.0136 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.0459) %, meaning that it generated no profit with money invested by stockholders. Koninklijke Philips' management efficiency ratios could be used to measure how well Koninklijke Philips manages its routine affairs as well as how well it operates its assets and liabilities. The Koninklijke Philips' current Return On Tangible Assets is estimated to increase to -0.03. The Koninklijke Philips' current Return On Capital Employed is estimated to increase to -0.0052. At this time, Koninklijke Philips' Intangible Assets are most likely to increase significantly in the upcoming years. The Koninklijke Philips' current Other Assets is estimated to increase to about 2.5 B, while Non Currrent Assets Other are projected to decrease to roughly 2.8 B.Similar Executives
| Showing other executives | INSIDER Age | ||
| Barbara Schwarzentraub | CONMED | 53 | |
| Dara Wright | Bio Rad Laboratories | 48 | |
| Myra Eskes | Smith Nephew SNATS | 49 | |
| Paul Stellato | Zimmer Biomet Holdings | 49 | |
| Andrew Hykes | Inari Medical | 51 | |
| MSc MD | Medtronic PLC | N/A | |
| John Rondoni | Inspire Medical Systems | 44 | |
| Andrew Swift | Smith Nephew plc | N/A | |
| Stacey Desrochers | Bruker | N/A | |
| Catherine Jennings | Boston Scientific Corp | N/A | |
| Philip Cowdy | Smith Nephew SNATS | 57 | |
| Spencer Stiles | Stryker | 47 | |
| Mary Moreland | Abbott Laboratories | 58 | |
| Laverne Council | CONMED | 59 | |
| McAlister Marshall | Integer Holdings Corp | 51 | |
| Alejandro Wellisch | Abbott Laboratories | 49 | |
| Christopher Scoggins | Abbott Laboratories | 54 | |
| Michael Dale | Abbott Laboratories | 61 | |
| John Zangerle | STERIS plc | 57 | |
| L Katz | Glaukos Corp | N/A | |
| J Pierce | Stryker | 47 | |
Management Performance
| Return On Equity | -0.0459 | ||||
| Return On Asset | 0.0136 |
Koninklijke Philips Leadership Team
Elected by the shareholders, the Koninklijke Philips' board of directors comprises two types of representatives: Koninklijke Philips inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Koninklijke. The board's role is to monitor Koninklijke Philips' management team and ensure that shareholders' interests are well served. Koninklijke Philips' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Koninklijke Philips' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Robert Cascella, Executive Vice President, Strategic Business Development Leader | ||
| Willem Appelo, Chief Officer | ||
| Leandro Mazzoni, Head Relations | ||
| Neelam Dhawan, Independent Member of the Supervisory Board | ||
| Andy Ho, Executive Vice President, Chief Market Leader of Philips Greater China | ||
| Roy Jakobs, Executive Vice President Chief Business Leader - Personal Health | ||
| M Doherty, Independent Member of the Shariah Supervisory Board | ||
| Shez Partovi, Executive Vice President Chief Innovation and Strategy Officer | ||
| Bert Meurs, Executive Vice President, Chief Business Leader Image Guided Therapy and jointly responsible for Diagnosis & Treatment | ||
| Indra Nooyi, Independent Member of the Supervisory Board | ||
| Pim Preesman, Head of Investor Relations | ||
| Vitor Rocha, Executive Vice President, Chief Market Leader of Philips North America | ||
| Peter Loescher, Independent Member of the Supervisory Board | ||
| Sophie Bechu, Executive Vice President, Chief Operations Officer | ||
| Sock Chua, Independent Member of the Supervisory Board | ||
| Jeroen Veer, Independent Chairman of the Supervisory Board | ||
| Daniela Seabrook, Chief Human Resource Officer, Executive Vice President | ||
| Marnix Ginneken, Executive Vice President, Chief Legal & Compliance Officer, Member of the Management Board, Secretary | ||
| Christine Poon, Vice Chairman of the Supervisory Board, Secretary, Member of Corporate Governance, Nomination and Selection Committee and Member of Remuneration Committee | ||
| Henk Jong, Executive Vice President, Chief Executive Officer - Philips Domestic Appliances | ||
| A Harrison, Independent Member of the Supervisory Board | ||
| Kees Wesdorp, Executive Vice President Chief Business Leader Precision Diagnosis and jointly responsible for Diagnosis & Treatment | ||
| Orit Gadiesh, Independent Member of the Supervisory Board | ||
| Jeroen Tas, Executive Vice President Chief Innovation and Strategy Officer | ||
| Deeptha Khanna, Executive Vice President, Chief Business Leader of Personal Health | ||
| Heidi Sichien, Executive Officer | ||
| Paulus Stoffels, Independent Vice Chairman of the Supervisory Board, Secretary | ||
| Jan Kimpen, Chief Officer | ||
| Charlotte Hanneman, CFO VP | ||
| Franois Houten, Advisor | ||
| Francois Houten, President, Chief Executive Officer and Chairman of the Board of Management | ||
| Edwin Paalvast, Executive Vice President, Chief of International Markets | ||
| Sean Carney, Chief Officer | ||
| Feike Sijbesma, Independent Vice Chairman of the Supervisory Board | ||
| Abhijit Bhattacharya, Executive Vice President & Chief Financial Officer, Member of the Management Board | ||
| Carla Kriwet, Executive Vice President Chief Business Leader of Connected Care & Health Informatics (CCHI) Businesses | ||
| David Pyott, Independent Member of the Supervisory Board |
Koninklijke Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Koninklijke Philips a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0459 | ||||
| Return On Asset | 0.0136 | ||||
| Profit Margin | (0.02) % | ||||
| Operating Margin | 0.08 % | ||||
| Current Valuation | 31.46 B | ||||
| Shares Outstanding | 931.89 M | ||||
| Shares Owned By Institutions | 6.87 % | ||||
| Number Of Shares Shorted | 2.58 M | ||||
| Price To Earning | 33.57 X | ||||
| Price To Book | 1.95 X |
Currently Active Assets on Macroaxis
When determining whether Koninklijke Philips is a strong investment it is important to analyze Koninklijke Philips' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Koninklijke Philips' future performance. For an informed investment choice regarding Koninklijke Stock, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Koninklijke Philips NV. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Koninklijke Philips. If investors know Koninklijke will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Koninklijke Philips listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.069 | Earnings Share (0.51) | Revenue Per Share 19.75 | Quarterly Revenue Growth (0.02) | Return On Assets 0.0136 |
The market value of Koninklijke Philips is measured differently than its book value, which is the value of Koninklijke that is recorded on the company's balance sheet. Investors also form their own opinion of Koninklijke Philips' value that differs from its market value or its book value, called intrinsic value, which is Koninklijke Philips' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Koninklijke Philips' market value can be influenced by many factors that don't directly affect Koninklijke Philips' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Koninklijke Philips' value and its price as these two are different measures arrived at by different means. Investors typically determine if Koninklijke Philips is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Koninklijke Philips' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.